Impulsivity, a key symptom and characteristic of attention-deficit hyperactivity disorder (ADHD), is a multifactorial construct including motor impulsivity and cognitive impulsivity. Although motor and hyperactivity symptoms seem to decline with progression into adulthood, cognitive impulsivity (i.e. impulsive decision-making) remains prominent in adult ADHD and is associated with a range of clinical consequences (e.g. poor relational or professional stability). A recent study reported that impulsivity was positively associated with the availability of striatal dopamine transporters, although this was not replicated in a larger study. In adults with ADHD, increased dopamine transporter availability was observed, but a recent meta-analysis suggested that this increase was driven by patients that were previously medicated. Methylphenidate – widely prescribed for the treatment of childhood ADHD but more debated as to its use in adult populations – binds to dopamine transporters and reduces symptoms of ADHD. However, there is no direct evidence that dopamine transporter occupancy by methylphenidate is associated with a reduction of impulsivity symptoms in the cognitive and/or motor domains of impulsivity. In this study, we investigated whether striatal dopamine transporter occupancy by methylphenidate is related to improvements in the distinct domains of cognitive and motor impulsivity.

Method

A total of 24 male medication-naïve adult patients with ADHD were included in the study. Recruitment, diagnosis and inclusion/exclusion criteria are described elsewhere (trial registered with Nederlands Trial Register, NTR3127). Eight patients had a comorbid diagnosis of cocaine dependence and were abstinent for >2 weeks prior to inclusion and no other psychiatric comorbidities were present. Striatal dopamine transporter availability and impulsivity levels were assessed at baseline (before medication) and after a 2-week treatment with extended-release methylphenidate (MPH-OROS 54 mg). Dopamine transporter availability (BPND) was assessed on a brain-dedicated single-photon emission computed tomography system using the caudate and putamen as regions of interest. A structural magnetic resonance imaging scan was made of each patient for co-registration. On the last treatment day, BPND was assessed 5 h after supervised intake of the last methylphenidate tablet and dopamine transporter occupancy by methylphenidate was calculated as previously described. Cognitive and motor impulsivity were assessed using a delayed discounting task and a stop-signal task respectively. The outcome measures were the discounting rate $k$ as a measure of cognitive impulsivity (where higher $k$ values represent higher cognitive impulsivity) and the Stop Signal Reaction Time (SSRT) as a measure of speed of inhibition to assess motor impulsivity. Impulsivity was measured at baseline and reassessed on the last day in the hour prior to dopamine transporter imaging. Improvement in impulsivity measures were calculated relative to baseline. The study was approved by the ethical committee of the Academic Medical Centre of the University of Amsterdam.

Statistics were performed using SPSS version 20 for Windows. Changes in impulsivity following methylphenidate were analysed using paired sample $t$-tests. Linear regression analyses were performed to assess the relationship between dopamine transporter occupancy by methylphenidate in striatal regions (dependent variable) and improvements in primary outcome measures on impulsivity tasks following methylphenidate (independent variables). Analyses were carried out separately for caudate and putamen (mean left and right sides). Separate analyses were performed for patients with ADHD with and without a comorbid diagnosis of cocaine dependence. An alpha of 0.05 was set as statistically significant.

Results

Our entire sample was male, 34 (s.d. = 6) years old, had a mean of 10 (s.d. = 4) years of education and an IQ of 105 (s.d. = 5). Body mass index was 26 kg/m² (s.d. = 4). One patient was diagnosed with the hyperactive ADHD subtype, 10 with the inattentive subtype and 13 with combined ADHD subtype. Patients had a mean ADHD Symptom Rating Scale score of 12 (s.d. = 4), indicating substantial severity of ADHD symptoms. Eleven patients were smokers and had a nicotine dependency score of 5 (s.d. = 2) on the Fagerstrom Test for Nicotine Dependence. Patients scored 82 (s.d. = 13) on the Barratt Impulsiveness Scale, indicating substantial impulsivity.

Following methylphenidate, $\text{BP}_{\text{ND}}$ decreased with 33% (s.d. = 16) and 41% (s.d. = 12) in the putamen and caudate nucleus respectively, indicating substantial dopamine transporter occupancy by methylphenidate. Following methylphenidate treatment, the discounting rate $k$ decreased significantly ($t = -2.31$; d.f. = 23; $P = 0.030$) and this decrease correlated significantly with dopamine transporter occupancy by methylphenidate in the putamen ($B = 618.71$; $t = 2.98$; $P = 0.010$), but not in the caudate ($P = 0.460$; not significant). The SSRT also decreased significantly following methylphenidate treatment ($t = -2.46$; d.f. = 23; $P = 0.023$), but changes were not correlated with dopamine transporter occupancy by methylphenidate in putamen or caudate (both $P > 0.389$; not significant). In an
exploratory analysis, we found that the correlation of dopamine transporter occupancy by methylphenidate with the discounting rate \( k \) (in the putamen) was stronger in patients without cocaine dependence (\( B = 4.435.27; t = 4.38; P = 0.001 \)) than in those with cocaine dependence (\( B = 495.23; t = 2.53; P = 0.045 \); online Fig. D1). No other correlations were observed between dopamine transporter occupancy by methylphenidate in putamen/caudate nucleus with cognitive or motor impulsivity measures for subgroups of patients with or without cocaine dependence (all \( P > 0.267 \); not significant).

**Discussion**

This report provides preliminary evidence that dopamine transporter occupancy by methylphenidate in the putamen drives improvements in cognitive impulsivity in male adult patients with ADHD, i.e. that a higher occupancy of dopamine transporters by methylphenidate leads to better cognitive impulsivity. In contrast, motor impulsivity was not correlated with dopamine transporter occupancy by methylphenidate in putamen or caudate. Although the putamen is traditionally associated with the ‘motor loop’ of the corticobasal ganglia-thalamic circuit, more recent studies also suggest a role of the putamen in salience pathways (i.e. orbitofrontal cortex, insula, anterior cingulate gyrus), especially in patients with ADHD.\(^{13,14}\) Yu suggested an additional pathway within patients with ADHD connecting left insula and left anterior cingulate gyrus via frontal gyrus and putamen.\(^{14}\) Through this pathway, changes in putamen function may modulate salience behaviour, including delay discounting. Our findings are in line with this hypothesis, but clearly need replication.

In previous studies in adult ADHD, dopamine transporter occupancy by methylphenidate (\( 3 \times 5 \) mg) ranges between 29 and 51%;\(^{15}\) with wide variability in dopamine transporter occupancy from one dose. One explanation for this variability may be differences in body weight between participants, while the methylphenidate dose was not weight-corrected. However, *post hoc*, we did not find a statistically significant association between body weight and dopamine transporter occupancy (\( P > 0.115 \)). It is also likely that there will be differences between patients in the rate they can metabolise methylphenidate (fast v. slow). Also, previous ADHD treatments as well as the severity of ADHD symptoms may lead to conformational changes in the dopamine transporter, and consequently to changes in dopamine transporter occupancy by methylphenidate. Further studies may test these postulates.

Clinically, deficits in cognitive impulsivity have devastating effects on a patient’s life choices (i.e. risk-taking) and life quality. Our data suggest a benefit of methylphenidate specifically on these impulsivity tasks. One explanation for this variability may be differences in body weight between participants, while the methylphenidate dose was not weight-corrected. However, *post hoc*, we did not find a statistically significant association between body weight and dopamine transporter occupancy (\( P > 0.115 \)). It is also likely that there will be differences between patients in the rate they can metabolise methylphenidate (fast v. slow). Also, previous ADHD treatments as well as the severity of ADHD symptoms may lead to conformational changes in the dopamine transporter, and consequently to changes in dopamine transporter occupancy by methylphenidate. Further studies may test these postulates.

Clinically, deficits in cognitive impulsivity have devastating effects on a patient’s life choices (i.e. risk-taking) and life quality. Our data suggest a benefit of methylphenidate specifically on these impulsivity tasks. One explanation for this variability may be differences in body weight between participants, while the methylphenidate dose was not weight-corrected. However, *post hoc*, we did not find a statistically significant association between body weight and dopamine transporter occupancy (\( P > 0.115 \)). It is also likely that there will be differences between patients in the rate they can metabolise methylphenidate (fast v. slow). Also, previous ADHD treatments as well as the severity of ADHD symptoms may lead to conformational changes in the dopamine transporter, and consequently to changes in dopamine transporter occupancy by methylphenidate. Further studies may test these postulates.

Clinically, deficits in cognitive impulsivity have devastating effects on a patient’s life choices (i.e. risk-taking) and life quality. Our data suggest a benefit of methylphenidate specifically on these impulsivity tasks. One explanation for this variability may be differences in body weight between participants, while the methylphenidate dose was not weight-corrected. However, *post hoc*, we did not find a statistically significant association between body weight and dopamine transporter occupancy (\( P > 0.115 \)). It is also likely that there will be differences between patients in the rate they can metabolise methylphenidate (fast v. slow). Also, previous ADHD treatments as well as the severity of ADHD symptoms may lead to conformational changes in the dopamine transporter, and consequently to changes in dopamine transporter occupancy by methylphenidate. Further studies may test these postulates.

Clinically, deficits in cognitive impulsivity have devastating effects on a patient’s life choices (i.e. risk-taking) and life quality. Our data suggest a benefit of methylphenidate specifically on these impulsivity tasks. One explanation for this variability may be differences in body weight between participants, while the methylphenidate dose was not weight-corrected. However, *post hoc*, we did not find a statistically significant association between body weight and dopamine transporter occupancy (\( P > 0.115 \)). It is also likely that there will be differences between patients in the rate they can metabolise methylphenidate (fast v. slow). Also, previous ADHD treatments as well as the severity of ADHD symptoms may lead to conformational changes in the dopamine transporter, and consequently to changes in dopamine transporter occupancy by methylphenidate. Further studies may test these postulates.

Clinically, deficits in cognitive impulsivity have devastating effects on a patient’s life choices (i.e. risk-taking) and life quality. Our data suggest a benefit of methylphenidate specifically on these impulsivity tasks. One explanation for this variability may be differences in body weight between participants, while the methylphenidate dose was not weight-corrected. However, *post hoc*, we did not find a statistically significant association between body weight and dopamine transporter occupancy (\( P > 0.115 \)). It is also likely that there will be differences between patients in the rate they can metabolise methylphenidate (fast v. slow). Also, previous ADHD treatments as well as the severity of ADHD symptoms may lead to conformational changes in the dopamine transporter, and consequently to changes in dopamine transporter occupancy by methylphenidate. Further studies may test these postulates.

Clinically, deficits in cognitive impulsivity have devastating effects on a patient’s life choices (i.e. risk-taking) and life quality. Our data suggest a benefit of methylphenidate specifically on these impulsivity tasks. One explanation for this variability may be differences in body weight between participants, while the methylphenidate dose was not weight-corrected. However, *post hoc*, we did not find a statistically significant association between body weight and dopamine transporter occupancy (\( P > 0.115 \)). It is also likely that there will be differences between patients in the rate they can metabolise methylphenidate (fast v. slow). Also, previous ADHD treatments as well as the severity of ADHD symptoms may lead to conformational changes in the dopamine transporter, and consequently to changes in dopamine transporter occupancy by methylphenidate. Further studies may test these postulates.
Fig. DS1 Correlations between dopamine transporter occupancy by methylphenidate in the putamen and changes in cognitive impulsivity scores (discounting rate $k$) for patients with attention-deficit hyperactivity disorder (a) without and (b) with a comorbid diagnosis of cocaine dependence.
Dopamine transporter occupancy by methylphenidate and impulsivity in adult ADHD
Cleo L. Crunelle, Wim van den Brink, Geert Dom and Jan Booij
BJP 2014, 204:486-487.
Access the most recent version at DOI: 10.1192/bjp.bp.113.132977

Supplementary material can be found at:
http://bjp.rcpsych.org/content/suppl/2014/03/26/bjp.bp.113.132977.DC1

This article cites 16 articles, 0 of which you can access for free at:
http://bjp.rcpsych.org/content/204/6/486#BIBL

To obtain reprints or permission to reproduce material from this paper, please write to permissions@rcpsych.ac.uk

You can respond to this article at
http://bjp.rcpsych.org/letters-submit/bjprcpsych;204/6/486

The Royal College of Psychiatrists

To subscribe to The British Journal of Psychiatry go to:
http://bjp.rcpsych.org/site/subscriptions/